Symbols / EQ
EQ Chart
About
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 96.82M |
| Enterprise Value | 63.23M | Income | -24.42M | Sales | 4.39M |
| Book/sh | 0.51 | Cash/sh | 0.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 35 | IPO | — |
| P/E | — | Forward P/E | -2.36 | PEG | — |
| P/S | 22.04 | P/B | 3.12 | P/C | — |
| EV/EBITDA | -2.61 | EV/Sales | 14.40 | Quick Ratio | 10.74 |
| Current Ratio | 10.85 | Debt/Eq | 2.41 | LT Debt/Eq | — |
| EPS (ttm) | -0.58 | EPS next Y | -0.68 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -44.17% |
| ROE | -90.24% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.55% | Profit Margin | 0.00% | Shs Outstand | 60.89M |
| Shs Float | 29.88M | Short Float | 2.80% | Short Ratio | 2.18 |
| Short Interest | — | 52W High | 2.35 | 52W Low | 0.27 |
| Beta | 1.85 | Avg Volume | 665.06K | Volume | 220.18K |
| Target Price | $2.50 | Recom | Buy | Prev Close | $1.57 |
| Price | $1.59 | Change | 1.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.50
Mean price target
2. Current target
$1.59
Latest analyst target
3. DCF / Fair value
$-3.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.59
Low
$1.00
High
$4.00
Mean
$2.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-28 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2024-11-01 | down | Jones Trading | Buy → Hold | — |
| 2024-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-12-26 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-13 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-08-14 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-05-01 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2023-03-24 | main | Stifel | — → Buy | $7 |
| 2023-02-08 | main | SVB Leerink | — → Outperform | $7 |
| 2022-09-27 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2022-09-08 | main | SVB Leerink | — → Outperform | $12 |
| 2022-03-24 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2022-01-05 | main | SVB Leerink | — → Outperform | $14 |
| 2021-09-15 | init | Cantor Fitzgerald | — → Overweight | $14 |
| 2021-03-03 | init | JonesTrading | — → Buy | $14 |
News
RSS: Latest EQ news- MLGEQ.PA Gentlemen’s Eq SA EURONEXT -17.39% intraday 17 Feb 2026: liquidity risk - Meyka ue, 17 Feb 2026 11
- $EQ stock is up 23% today. Here's what we see in our data. - Quiver Quantitative Wed, 10 Dec 2025 08
- EQIX Stock Target Price Raised by Wells Fargo Analyst Today | EQ - GuruFocus hu, 12 Feb 2026 15
- EQ (CVE:EQ) Stock Price Down 2.1% - Should You Sell? - MarketBeat Fri, 06 Feb 2026 08
- Shareholder services - Bristol Myers Squibb Wed, 14 May 2025 07
- Is EQ Resources’ (ASX:EQR) Boardroom Challenge Reframing Its Capital Strategy And Investor Voice? - simplywall.st Sun, 15 Feb 2026 16
- EQB.TO Stock Today: February 16 – PC Financial Deal Targets Scale - Meyka ue, 17 Feb 2026 02
- Shopify Inc. $SHOP Stock Position Lifted by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat Fri, 06 Feb 2026 08
- IQ EQ FUND MANAGEMENT IRELAND Ltd Trims Stock Position in HCA Healthcare, Inc. $HCA - MarketBeat Sat, 07 Feb 2026 08
- IQ EQ FUND MANAGEMENT IRELAND Ltd Has $22.41 Million Stock Holdings in Robinhood Markets, Inc. $HOOD - MarketBeat Fri, 06 Feb 2026 08
- IQ EQ FUND MANAGEMENT IRELAND Ltd Decreases Stock Holdings in Cummins Inc. $CMI - MarketBeat Fri, 06 Feb 2026 08
- IQ EQ FUND MANAGEMENT IRELAND Ltd Has $4.78 Million Stock Holdings in Veracyte, Inc. $VCYT - MarketBeat Fri, 06 Feb 2026 08
- IQ EQ FUND MANAGEMENT IRELAND Ltd Has $8.66 Million Stock Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat Fri, 06 Feb 2026 08
- IQ EQ FUND MANAGEMENT IRELAND Ltd Has $1.48 Million Stock Holdings in HA Sustainable Infrastructure Capital, Inc. $HASI - MarketBeat Sat, 07 Feb 2026 08
- IQ EQ FUND MANAGEMENT IRELAND Ltd Has $46.27 Million Stock Holdings in Taiwan Semiconductor Manufacturing Company Ltd. $TSM - MarketBeat Fri, 06 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6533 | 8428 | — | Sale at price 1.29 per share. | TOM PENNY | Officer | — | 2026-01-08 00:00:00 | D |
| 1 | 100000 | 150000 | — | Sale at price 1.50 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-23 00:00:00 | D |
| 2 | 100000 | 78500 | — | Conversion of Exercise of derivative security at price 0.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-23 00:00:00 | D |
| 3 | 35704 | 47486 | — | Sale at price 1.31 - 1.34 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-15 00:00:00 | D |
| 4 | 8098 | 7696 | — | Sale at price 0.95 - 0.98 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-11-25 00:00:00 | D |
| 5 | 10000 | 6500 | — | Sale at price 0.65 per share. | KEYES JASON A | Chief Financial Officer | — | 2025-01-23 00:00:00 | I |
| 6 | 15000 | 10518 | — | Stock Award(Grant) at price 0.70 per share. | KEYES JASON A | Chief Financial Officer | — | 2024-12-10 00:00:00 | D |
| 7 | 10000 | 7000 | — | Sale at price 0.70 per share. | KEYES JASON A | Chief Financial Officer | — | 2024-11-14 00:00:00 | I |
| 8 | 15000 | 18750 | — | Sale at price 1.25 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2024-10-28 00:00:00 | D |
| 9 | 3518 | 4398 | — | Sale at price 1.25 per share. | TOM PENNY | Officer | — | 2024-10-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -7.57M | -12.14M | -38.21M | -37.91M |
| TotalUnusualItems | 0.00 | -23.05M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -23.05M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.07M | -13.34M | -62.43M | -39.05M |
| ReconciledDepreciation | 137.00K | 126.00K | 118.00K | 72.00K |
| EBITDA | -7.57M | -12.14M | -61.26M | -37.91M |
| EBIT | -7.71M | -12.26M | -61.38M | -37.98M |
| NetInterestIncome | 1.38M | 1.84M | -633.00K | -1.02M |
| InterestExpense | 0.00 | 491.00K | 1.05M | 1.07M |
| InterestIncome | 1.38M | 2.33M | 420.00K | 57.00K |
| NormalizedIncome | -8.07M | -13.34M | -39.38M | -39.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.07M | -13.34M | -62.43M | -39.05M |
| TotalExpenses | 49.36M | 50.61M | 54.79M | 37.79M |
| TotalOperatingIncomeAsReported | -8.27M | -14.52M | -62.08M | -37.79M |
| DilutedAverageShares | 35.36M | 34.73M | 33.73M | 28.81M |
| BasicAverageShares | 35.36M | 34.73M | 33.73M | 28.81M |
| DilutedEPS | -0.23 | -0.38 | -1.85 | -1.36 |
| BasicEPS | -0.23 | -0.38 | -1.85 | -1.36 |
| DilutedNIAvailtoComStockholders | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeCommonStockholders | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncome | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeIncludingNoncontrollingInterests | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeContinuousOperations | -8.07M | -13.34M | -62.43M | -39.05M |
| TaxProvision | 361.00K | 580.00K | 0.00 | |
| PretaxIncome | -7.71M | -12.76M | -62.43M | -39.05M |
| OtherIncomeExpense | -818.00K | -76.00K | -22.77M | -250.00K |
| OtherNonOperatingIncomeExpenses | -818.00K | -76.00K | 281.00K | -250.00K |
| SpecialIncomeCharges | 0.00 | -23.05M | 0.00 | |
| OtherSpecialCharges | 23.05M | |||
| NetNonOperatingInterestIncomeExpense | 1.38M | 1.84M | -633.00K | -1.02M |
| InterestExpenseNonOperating | 0.00 | 491.00K | 1.05M | 1.07M |
| InterestIncomeNonOperating | 1.38M | 2.33M | 420.00K | 57.00K |
| OperatingIncome | -8.27M | -14.52M | -39.03M | -37.79M |
| OperatingExpense | 49.36M | 50.61M | 54.79M | 37.79M |
| ResearchAndDevelopment | 37.43M | 37.04M | 37.55M | 26.38M |
| SellingGeneralAndAdministration | 11.94M | 13.57M | 17.24M | 11.41M |
| GeneralAndAdministrativeExpense | 11.94M | 13.57M | 17.24M | 11.41M |
| OtherGandA | 11.94M | 13.57M | 17.24M | 11.41M |
| TotalRevenue | 41.09M | 36.08M | 15.76M | 0.00 |
| OperatingRevenue | 41.09M | 36.08M | 15.76M | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 35.56M | 35.25M | 34.41M | 29.46M |
| ShareIssued | 35.56M | 35.25M | 34.41M | 29.46M |
| TotalDebt | 384.00K | 824.00K | 10.19M | 11.79M |
| TangibleBookValue | 19.06M | 22.57M | 31.94M | 66.50M |
| InvestedCapital | 19.06M | 22.57M | 40.90M | 76.68M |
| WorkingCapital | 18.62M | 21.78M | 44.70M | 74.45M |
| NetTangibleAssets | 19.06M | 22.57M | 31.94M | 66.50M |
| CapitalLeaseObligations | 384.00K | 824.00K | 1.23M | 1.61M |
| CommonStockEquity | 19.06M | 22.57M | 31.94M | 66.50M |
| TotalCapitalization | 19.06M | 22.57M | 35.18M | 75.25M |
| TotalEquityGrossMinorityInterest | 19.06M | 22.57M | 31.94M | 66.50M |
| StockholdersEquity | 19.06M | 22.57M | 31.94M | 66.50M |
| GainsLossesNotAffectingRetainedEarnings | 781.00K | 140.00K | 76.00K | -138.00K |
| OtherEquityAdjustments | 781.00K | 140.00K | 76.00K | -138.00K |
| RetainedEarnings | -193.81M | -185.74M | -172.41M | -109.98M |
| AdditionalPaidInCapital | 212.08M | 208.17M | 204.27M | 176.62M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 2.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 6.54M | 27.96M | 46.48M | 18.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 187.00K | 384.00K | 14.44M | 9.98M |
| NonCurrentDeferredLiabilities | 0.00 | 10.38M | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 10.38M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 187.00K | 384.00K | 4.06M | 9.98M |
| LongTermCapitalLeaseObligation | 187.00K | 384.00K | 824.00K | 1.24M |
| LongTermDebt | 3.24M | 8.75M | ||
| CurrentLiabilities | 6.36M | 27.57M | 32.04M | 8.91M |
| CurrentDeferredLiabilities | 0.00 | 15.73M | 14.70M | 0.00 |
| CurrentDeferredRevenue | 0.00 | 15.73M | 14.70M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 197.00K | 440.00K | 6.12M | 1.80M |
| CurrentCapitalLeaseObligation | 197.00K | 440.00K | 408.00K | 376.00K |
| CurrentDebt | 5.71M | 1.43M | ||
| OtherCurrentBorrowings | 5.71M | 1.43M | ||
| PayablesAndAccruedExpenses | 6.16M | 11.40M | 11.22M | 7.11M |
| CurrentAccruedExpenses | 3.12M | 6.70M | 7.24M | 5.89M |
| InterestPayable | 0.00 | 74.00K | 71.00K | |
| Payables | 3.04M | 4.71M | 3.98M | 1.23M |
| TotalTaxPayable | 365.00K | 0.00 | ||
| IncomeTaxPayable | 365.00K | 0.00 | ||
| AccountsPayable | 2.68M | 4.71M | 3.98M | 1.23M |
| TotalAssets | 25.60M | 50.53M | 78.42M | 85.41M |
| TotalNonCurrentAssets | 626.00K | 1.18M | 1.69M | 2.04M |
| OtherNonCurrentAssets | 70.00K | 104.00K | 153.00K | |
| NetPPE | 626.00K | 1.11M | 1.58M | 1.88M |
| AccumulatedDepreciation | -499.00K | -364.00K | -249.00K | -147.00K |
| GrossPPE | 1.12M | 1.48M | 1.83M | 2.03M |
| Leases | 20.00K | 20.00K | 20.00K | 0.00 |
| OtherProperties | 364.00K | 796.00K | 1.19M | 1.65M |
| MachineryFurnitureEquipment | 741.00K | 659.00K | 620.00K | 384.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 24.98M | 49.35M | 76.73M | 83.37M |
| OtherCurrentAssets | 429.00K | 235.00K | 8.00K | 2.66M |
| PrepaidAssets | 830.00K | 1.96M | 1.59M | 2.66M |
| Receivables | 1.14M | 6.29M | 4.11M | 0.00 |
| OtherReceivables | 178.00K | 497.00K | 269.00K | |
| TaxesReceivable | 966.00K | 2.05M | 1.01M | |
| AccountsReceivable | 0.00 | 3.73M | 2.84M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 22.57M | 40.87M | 71.02M | 80.71M |
| OtherShortTermInvestments | 4.49M | 17.65M | 11.92M | 30.34M |
| CashAndCashEquivalents | 18.09M | 23.22M | 59.11M | 50.37M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.11M | -21.83M | -9.01M | -32.14M |
| RepurchaseOfCapitalStock | 0.00 | -260.00K | 0.00 | |
| RepaymentOfDebt | 0.00 | -9.13M | -1.43M | |
| IssuanceOfCapitalStock | 0.00 | 29.91M | ||
| CapitalExpenditure | -85.00K | -50.00K | -279.00K | -57.00K |
| InterestPaidSupplementalData | 0.00 | 946.00K | 847.00K | 836.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 580.00K | 0.00 | |
| EndCashPosition | 18.09M | 23.22M | 59.11M | 50.37M |
| BeginningCashPosition | 23.22M | 59.11M | 50.37M | 23.98M |
| EffectOfExchangeRateChanges | -83.00K | -118.00K | 5.00K | -2.00K |
| ChangesInCash | -5.05M | -35.77M | 8.74M | 26.39M |
| FinancingCashFlow | 164.00K | -9.23M | -1.22M | 31.06M |
| CashFlowFromContinuingFinancingActivities | 164.00K | -9.23M | -1.22M | 31.06M |
| ProceedsFromStockOptionExercised | 164.00K | 165.00K | 214.00K | 1.15M |
| NetCommonStockIssuance | 0.00 | -260.00K | 0.00 | 29.91M |
| CommonStockPayments | 0.00 | -260.00K | 0.00 | |
| CommonStockIssuance | 0.00 | 29.91M | ||
| NetIssuancePaymentsOfDebt | 0.00 | -9.13M | -1.43M | |
| NetLongTermDebtIssuance | 0.00 | -9.13M | -1.43M | |
| LongTermDebtPayments | 0.00 | -9.13M | -1.43M | |
| InvestingCashFlow | 13.81M | -4.76M | 18.68M | 27.41M |
| CashFlowFromContinuingInvestingActivities | 13.81M | -4.76M | 18.68M | 27.41M |
| NetInvestmentPurchaseAndSale | 13.90M | -4.71M | 18.26M | 27.46M |
| SaleOfInvestment | 31.50M | 50.00M | 33.23M | 60.45M |
| PurchaseOfInvestment | -17.60M | -54.71M | -14.96M | -32.99M |
| NetBusinessPurchaseAndSale | 0.00 | 700.00K | 0.00 | |
| SaleOfBusiness | 0.00 | 700.00K | 0.00 | |
| NetPPEPurchaseAndSale | -85.00K | -50.00K | -279.00K | -57.00K |
| PurchaseOfPPE | -85.00K | -50.00K | -279.00K | -57.00K |
| OperatingCashFlow | -19.03M | -21.78M | -8.73M | -32.08M |
| CashFlowFromContinuingOperatingActivities | -19.03M | -21.78M | -8.73M | -32.08M |
| ChangeInWorkingCapital | 842.00K | -2.55M | 19.00K | 1.70M |
| ChangeInOtherWorkingCapital | -9.00K | -13.00K | 75.00K | -37.00K |
| ChangeInOtherCurrentLiabilities | -151.00K | |||
| ChangeInOtherCurrentAssets | 114.00K | |||
| ChangeInPayablesAndAccruedExpense | -5.16M | 169.00K | 2.94M | 1.52M |
| ChangeInAccruedExpense | -3.16M | -554.00K | 432.00K | 3.10M |
| ChangeInPayable | -2.00M | 723.00K | 2.51M | -1.58M |
| ChangeInAccountPayable | -2.00M | 723.00K | 2.51M | -1.58M |
| ChangeInPrepaidAssets | 2.27M | -1.80M | -158.00K | 214.00K |
| ChangeInReceivables | 3.73M | -897.00K | -2.84M | 0.00 |
| ChangesInAccountReceivables | 3.73M | -897.00K | -2.84M | 0.00 |
| OtherNonCashItems | -15.73M | -9.17M | 48.33M | 237.00K |
| StockBasedCompensation | 3.75M | 4.00M | 4.84M | 4.41M |
| AmortizationOfSecurities | -754.00K | -914.00K | 127.00K | 314.00K |
| DepreciationAmortizationDepletion | 137.00K | 126.00K | 118.00K | 72.00K |
| DepreciationAndAmortization | 137.00K | 126.00K | 118.00K | 72.00K |
| Depreciation | 137.00K | 126.00K | 118.00K | |
| OperatingGainsLosses | 794.00K | 58.00K | 260.00K | 240.00K |
| NetForeignCurrencyExchangeGainLoss | 794.00K | 58.00K | 260.00K | 240.00K |
| NetIncomeFromContinuingOperations | -8.07M | -13.34M | -62.43M | -39.05M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EQ
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|